Pfanstiehl, Inc.
James A. Breckenridge is a seasoned executive with extensive experience in the healthcare and biopharmaceutical sectors. As the Chairman, Chief Executive Officer, and President of Pfanstiehl, Inc. since March 2013, Breckenridge leads a global provider of specialized products for biopharmaceutical applications, focusing on high-purity carbohydrates and amino acids. In addition, Breckenridge co-founded Med Opportunity Partners, LLC in 2007, a private equity firm dedicated to investing in healthcare companies, and served as Chairman of Reliable Biopharmaceutical Holdings, Inc. until December 2016. Prior to these roles, Breckenridge held positions at UBS Capital Americas, LLC and was an Associate at Kidder, Peabody & Company. Breckenridge holds an MBA in Finance from Columbia Business School and a BA in History from Colgate University.
This person is not in any teams
This person is not in any offices
Pfanstiehl, Inc.
1 followers
Founded in 1919 by Carl A. Pfanstiehl, our company specializes in isolation, purification, custom synthesis and scale-up development of cGMP, high purity and low endotoxin (HPLE) Injectable Formulation Components, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API’s), in gram to multi-ton commercial quantities. Tried and true parenteral excipients include trehalose, sucrose, mannitol, maltose, sorbitol, and hydroxypropyl betacyclodextrin. Upstream, high purity media components include animal component free galactose, mannose, and L-arginine. At Pfanstiehl we pride ourselves on being customer focused and are amenable to producing cGMP components on a custom basis to solve formulation challenges for our clients.